Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Amgen, Cytokinetics and Servier announce start of METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

worldpharmanewsFebruary 22, 2019

Tag: Amgen , Heart failure , Cytokinetics

PharmaSources Customer Service